Human cancers are known to have genetic alterations in components of multiple, intersecting signaling pathways, or networks, that are selected over several generations of cell division and support survival, growth, and invasion of the cancer cell. These genetic alterations afford the cancer cell a malignant phenotype, which results in the formation and maintenance of a tumor. We believe that targeting these critical components and signaling pathways, either singly or in combination could provide more effective drugs and improve outcomes for cancer patients. We are developing small molecule drug candidates that are either designed and discovered internally or acquired through in-licensing which target a number of critical components and pathways altered in different human cancers.
Curis is testing proprietary, clinical-stage small molecules for various cancers, including an oral antagonist of inhibitor of apoptosis (IAP) proteins, CUDC-427, and a dual phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) inhibitor, CUDC-907. The company also has an EGFR/Her2 and HDAC inhibitor, CUDC-101, in preclinical development.
Curis’ collaborator Genentech/Roche is commercializing Hedgehog pathway inhibitor Erivedge® (vismodegib) in the United States, European Union and various other territories for the treatment of patients with advanced basal cell carcinoma (BCC). Roche continues to seek approvals for Erivedge for the treatment of advanced BCC in several countries worldwide and is also testing Erivedge in less severe forms of BCC. In addition to BCC, there are clinical studies ongoing with Erivedge in other cancers, some of which are being conducted by Genentech/Roche and others are part of collaborations between Genentech and the National Cancer Institute and independent study investigators.
Curis’ licensee Debiopharm is also conducting clinical studies with our HSP90 inhibitor Debio 0932 in patients with advanced lung cancer and expects to initiate additional clinical trials in patients with renal cell carcinoma during the second half of 2013.